Rapidly growing pan-Latin American specialty pharmaceutical company
Biotoscana is a rapidly growing pan-Latin American specialty pharmaceutical company, headquartered in Bogotá, with operations across the region and a broad portfolio of high-value specialty pharmaceutical products as well as generics. Biotoscana was founded as a family owned business in 1994 and has expanded rapidly across the region. Today, Biotoscana has operations in Colombia, Brazil, Argentina, Chile, Ecuador and Peru. Biotoscana expanded into Brazil in 2014 when it agreed to acquire United Medical, a leading specialty pharma company focused on therapies to serve significant unmet needs. The company sells a mixture of specialty pharmaceuticals and branded generics and in recent years has increasingly focused on growing the specialty pharmaceutical business with novel, high-value products in-licensed from global pharmaceutical companies.
Essex Woodlands, together with Advent International, a leading Latin American private equity company, acquired a controlling stake in Biotoscana at the end of 2011. This is the first investment for Essex Woodlands in Latin America, a region in which economic growth, rising prosperity and government efforts are enabling an increasing number of people to gain access to healthcare.
Biotoscana is a rapidly growing pan-Latin American specialty pharmaceutical company, headquartered in Bogotá, with operations across the region and a broad portfolio of high-value specialty pharmaceutical products as well as generics. Biotoscana was founded as a family owned business in 1994 and has expanded rapidly across the region. Today, Biotoscana has operations in Colombia, Brazil, Argentina, Chile, Ecuador and Peru. Biotoscana expanded into Brazil in 2014 when it agreed to acquire United Medical, a leading specialty pharma company focused on therapies to serve significant unmet needs. The company sells a mixture of specialty pharmaceuticals and branded generics and in recent years has increasingly focused on growing the specialty pharmaceutical business with novel, high-value products in-licensed from global pharmaceutical companies.
Essex Woodlands, together with Advent International, a leading Latin American private equity company, acquired a controlling stake in Biotoscana at the end of 2011. This is the first investment for Essex Woodlands in Latin America, a region in which economic growth, rising prosperity and government efforts are enabling an increasing number of people to gain access to healthcare.
Location: Colombia, Bogota
Total raised: $417M
Investors 2
| Date | Name | Website |
| - | EW Healthc... | ewhealthca... |
| - | Advent Int... | adventinte... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.07.2017 | IPO | $417M | - |
Mentions in press and media 10
| Date | Title | Description |
| 29.11.2019 | Knight Therapeutics Announces Closing of Previously Announced Acquisition of Grupo Biotoscana | Nov 29 2019 MONTREAL, Canada—Knight Therapeutics Inc. (TSX: GUD) (“Knight”) today announced that it has completed the acquisition of a 51.2% interest in Biotoscana Investments S.A. (B3: GBIO33) (“GBT” or “Grupo Biotoscana”) from a controll... |
| 22.08.2019 | EW Healthcare Partners Raises Over $745 Million Fund 2 | Aug 22 2019 Team of Experienced Healthcare Investors and Former Healthcare Executives Will Invest in Select Healthcare Companies to Seek to Accelerate Their Revenue Growth Partner and Principals Promoted in London, New York and Palo Alto ... |
| 03.10.2017 | Grupo Biotoscana and EISAI Sign Licensing Agreement for Four Oncology & Neurology Products in LatAm | Oct 03 2017 MONTEVIDEO, Uruguay and WOODCLIFF LAKE, New Jersey—GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has entered into an exclusive licensing agreement with Eisai In... |
| 30.08.2017 | Grupo Biotoscana Expands Partnership with Gilead Sciences in HCV in Brazil | Aug 30 2017 Montevideo, Uruguay—GBT-Grupo Biotoscana (B3: GBIO33), a leading specialty pharmaceutical company in Latin America, today announced that it has expanded its partnership with Gilead Sciences (Nasdaq: GILD) in HCV in Brazil. Unde... |
| 21.07.2017 | Grupo Biotoscana Raises $417 Million in Oversubscribed Brazil IPO | Jul 21 2017 LONDON, United Kingdom—EW Healthcare Partners (“EWHP”), a global healthcare growth equity investor, announced that Grupo Biotoscana (“Biotoscana”), a Pan-Latin American specialty pharmaceutical company focused on oncology and c... |
| 25.07.2016 | Pierre Fabre Pharmaceuticals and Grupo Biotoscana enter into a Commercialization Agreement | Jul 25 2016 Castres (France) and Montevideo (Uruguay) – July 25, 2016 – Pierre Fabre Pharmaceuticals, the second-largest French private pharmaceutical laboratory and Grupo Biotoscana SL (GBT), a leading specialty pharmaceutical company in ... |
| 04.02.2016 | Grupo Biotoscana Advances Integration of Laboratorio LKM | Feb 04 2016 MONTEVIDEO – – Grupo Biotoscana SL (GBT), a leading specialty pharmaceutical company in Latin America, today announced continued progress in its integration of Laboratorio LKM (LKM) with an enhanced organizational structure and... |
| 21.12.2015 | Grupo Biotoscana acquires Laboratorio LKM | Dec 21 2015 MADRID AND BUENOS AIRES – Grupo Biotoscana SL, a leading specialty pharmaceutical company in Latin America, today announced that it has completed the acquisition of Laboratorio LKM S.A., a specialty pharmaceutical manufacturer ... |
| 13.01.2014 | Biotoscana Agrees to Acquire United Medical to Expand Commercial Presence in Brazil | Jan 13 2014 BOGOTÁ, COLOMBIA AND SÃO PAULO—Grupo Biotoscana SL, a pharmaceutical company based in Bogotá, Colombia, and majority owned by Advent International and Essex Woodlands, today announced that it has signed an agreement to acquire ... |
| 31.01.2012 | Lured by Rising Healthcare Demand, Essex Woodlands Enters Latin America | Jan 31 2012 BOGOTA, Colombia—With demand for health care rising across Latin America, Advent International and Essex Woodlands Health Ventures have acquired a controlling stake in Grupo Farmaceutico Biotoscana S.A. in a deal that will fuel... |